Omar Bashir, DO
Internal Medicine · Banning, CANPI 1891730479
Payments from drug & device makers
Across 443 payments — averaging $32.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- Novo Nordisk$2K
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- AstraZeneca$1K
- Boehringer Ingelheim$1K
- AbbVie$1K
- plus $3K from 23 others
Across 2 payments — averaging $225.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$450
What the payments were for
- Consulting fees$4,57632%
- Speaking & faculty fees$1,1208%
- Travel & lodging$2932%
- Food & beverage$8,13757%
- Education$650%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 21 | $3,880 |
| Novo Nordisk | 146 | $2,356 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $1,965 |
| AstraZeneca | 70 | $1,260 |
| Boehringer Ingelheim | 52 | $1,107 |
| AbbVie(2 entities) | 15 | $1,074 |
| Sanofi-aventis U.S. LLC | 29 | $661 |
| Pfizer | 44 | $603 |
| Bayer | 10 | $247 |
| Novartis | 11 | $242 |
| Lilly USA, LLC | 4 | $183 |
| Sanofi | 1 | $90 |
| Merck | 4 | $78 |
| E.r. Squibb & Sons, L.L.C. | 4 | $66 |
| Johnson & Johnson | 3 | $47 |
| Amarin Pharma, Inc. | 3 | $47 |
| Amgen | 2 | $45 |
| Astellas Pharma US Inc | 2 | $37 |
| Biocryst US Sales Co., LLC | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Nestle Healthcare Nutrition Inc. | 2 | $25 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Eko Health, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $18 |
| Almatica Pharma LLC | 1 | $18 |
| Eisai Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Circassia Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,191 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 518 | $417,701 |
| EliquisApixaban | 380 | $310,684 |
| OzempicSemaglutide | 239 | $251,784 |
| CreonLipase/Protease/Amylase | 41 | $103,510 |
| ZenpepLipase/Protease/Amylase | 27 | $89,352 |
| FarxigaDapagliflozin Propanediol | 87 | $81,899 |
| Egrifta SvTesamorelin Acetate | 11 | $77,904 |
| JanuviaSitagliptin Phosphate | 53 | $58,500 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $56,635 |
| Spiriva RespimatTiotropium Bromide | 83 | $53,190 |
| XareltoRivaroxaban | 49 | $49,859 |
| RybelsusSemaglutide | 42 | $43,075 |
| MyrbetriqMirabegron | 65 | $42,339 |
| TrulicityDulaglutide | 32 | $39,486 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 60 | $33,514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $1,107 | $489,333630 claims |
| PfizerEliquis, Premarin | $603 | $317,536392 claims |
| Novo NordiskOzempic, Rybelsus | $2,356 | $294,859281 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $1,260 | $131,107150 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $3,880 | $117,001183 claims |
| AbbVieCreon, Linzess | $1,074 | $110,64452 claims |
| MerckJanuvia, Belsomra | $78 | $79,67297 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $183 | $68,14458 claims |
| Johnson & JohnsonXarelto | $47 | $49,85949 claims |
| Astellas Pharma US IncMyrbetriq | $37 | $42,33965 claims |
| BayerKerendia | $247 | $10,19016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Banning
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.